Menu

Search

  |   Business

Menu

  |   Business

Search

Eli Lilly receives subpoena from DOJ for a case related to its manufacturing plant

Photo by: Eli Lilly/Facebook

Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.

As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.

The issue with Eli Lilly’s NJ plant

Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.

It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.

The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.

Lilly conducting its own internal probe

As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.

“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.

In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.

  • Market Data
Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.